NASDAQ: PTNPalatin Technologies Inc Stock
$8.90+0.05 (+0.56%)
Updated Jul 15, 2026
PTN Price
$8.90
Fair Value Price
$4.46
Market Cap
$15.84M
52 Week Low
$5.61
52 Week High
$31.00
P/E
2.59x
P/B
1.5x
P/S
5.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$12.88M
Earnings
-$6.25M
Gross Margin
100%
Operating Margin
-48.45%
Profit Margin
-48.5%
Debt to Equity
0.25
Operating Cash Flow
-$15M
Beta
1.13
Next Earnings
Aug 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PTN Overview
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PTN's potential to beat the market
- PTN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PTN
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $239.32 | A | |
| $10.73 | A | |
| $16.10 | A |
Be the first to know about important PTN news, forecast changes, insider trades & much more!
PTN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PTN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTN ($8.90) is overvalued by 99.6% relative to our estimate of its Fair Value price of $4.46 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PTN ($8.90) is not significantly undervalued (99.6%) relative to our estimate of its Fair Value price of $4.46 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PTN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more PTN due diligence checks available for Premium users.
Valuation
PTN fair value
Fair Value of PTN stock based on Discounted Cash Flow (DCF)
Price
$8.90
Fair Value
$4.46
Overvalued by
99.60%
PTN ($8.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PTN ($8.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PTN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.59x
Industry
18.63x
Market
9.1x
PTN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PTN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PTN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.5x
Industry
5.46x
PTN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PTN's financial health
Profit margin
Revenue
$3.9M
Net Income
-$1.4M
Profit Margin
-36.5%
PTN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PTN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.2M
Liabilities
$2.6M
Debt to equity
0.25
PTN's short-term assets ($12.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTN's short-term assets ($12.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.4M
Investing
-$38.5k
Financing
$138.9k
PTN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PTN vs Biotech Stocks
Palatin Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.